Second FDA/Alzheimer’s Disease Allies Meeting

ACT-AD, together with the Alzheimer’s Association and LEAD (Leaders Engaged in Alzheimer’s Disease), hosted an FDA/Alzheimer’s Disease Allies Meeting to stimulate an open discussion with FDA officials, scientists, drug developers, academics and advocacy organizations on standards of clinical meaningfulness and exploring novel approaches regarding the state of the science in this vital field.
View Agenda
See Press Release
View Transcript
Read Neurology Today Article